New hope for Moms-to-Be with dangerous itching condition?
NCT ID NCT07389031
First seen Feb 05, 2026 · Last updated Apr 28, 2026 · Updated 13 times
Summary
This early-phase trial tests whether maralixibat is safe and can reduce severe itching in pregnant women with intrahepatic cholestasis of pregnancy (ICP), a liver condition that raises bile acids. About 28 women with a single pregnancy between 20 and 35 weeks will take the drug. The main goal is to check for side effects and see if itching improves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLESTASIS OF PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Birmingham Womens and Childrens NHS Foundation Trust
Birmingham, B15 2TG, United Kingdom
-
Guy's and St Thomas' NHS Foundation Trust
London, SE 1 7EH, United Kingdom
Conditions
Explore the condition pages connected to this study.